Integer Forecasts 2024 Sales Of $1.735B-$1.77B Versus Consensus Of $1.757B With Adjusted EPS Of $5.07-$5.49 Versus Consensus Of $5.29
$ITGR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
2024 Outlook(a)
| (dollars in millions, except per share amounts) | GAAP | Non-GAAP(b) | ||||
| As Reported | Change from Prior Year |
Adjusted | Change from Prior Year |
|||
| Sales | $1,735 to $1,770 | 9% to 11% | N/A | N/A | ||
| Operating income | $202 to $220 | 21% to 31% | $275 to $293 | 14% to 21% | ||
| EBITDA | N/A | N/A | $357 to $377 | 15% to 22% | ||
| Net income | $116 to $130 | 28% to 44% | $174 to $189 | 11% to 20% | ||
| Diluted earnings per share | $3.26 to $3.67 | 21% to 37% | $5.07 to $5.49 | 9% to 18% | ||
| Cash flow from operating activities | $185 to $205 | 3% to 14% | N/A | N/A | ||